1-(3,5-dimethoxyphenyl)-1,4-diazepane | 882695-41-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,5-dimethoxyphenyl)-1,4-diazepane
• CAS: 882695-41-2
• 化学式: C₁₃H₂₀N₂O₂
• mdl: MFCD16208240
• 分子量: 236.314
• InChiKey: BNWBWXFWPXNZSW-UHFFFAOYSA-N

物化性质

• 沸点：
  395.8±42.0 °C(Predicted)
• 密度：
  1.057±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  33.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3,5-dimethoxyphenyl)-1,4-diazepane 、 4-(2-fluorophenyl)-2-methyloxazole-5-carboxylic acid 在 N-甲基吗啉 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 正丁醇 为溶剂， 反应 1.0h， 生成 [4-(3,5-dimethoxyphenyl)-1,4-diazepan-1-yl][4-(2-fluorophenyl)-2-methyloxazol-5-yl]methanone
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy

  摘要：

  A series of aryloxazole, thiazole, and isoxazole derivatives was synthesized as vascular-targeting anticancer agents. Antiproliferative activity and tumor vascular-disrupting activity of all of the synthesized compounds were tested in vitro using various human cancer cell lines and HUVECs (human umbilical vein endothelial cells). Several compounds with an arylpiperazinyl oxazole core showed excellent cytotoxicity and metabolic stability in vitro. Among this series, two representative compounds (6-48 and 6-51) were selected and tested for the evaluation of anticancer effects in vivo using tumor-bearing mice. Compound 6-48 effectively reduced tumor growth (42.3% reduction in size) at the dose of 100 mg/kg. We believe that compound 6-48 will serve as a good lead compound for antimitotic and vascular-disrupting agents; further investigation to improve the in vivo efficacy of this series is underway.

  DOI：

  10.1021/jm400840p
• 作为产物：
  描述：

  3,5-二甲氧基苯硼酸 在 copper diacetate 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-(3,5-dimethoxyphenyl)-1,4-diazepane
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy

  摘要：

  A series of aryloxazole, thiazole, and isoxazole derivatives was synthesized as vascular-targeting anticancer agents. Antiproliferative activity and tumor vascular-disrupting activity of all of the synthesized compounds were tested in vitro using various human cancer cell lines and HUVECs (human umbilical vein endothelial cells). Several compounds with an arylpiperazinyl oxazole core showed excellent cytotoxicity and metabolic stability in vitro. Among this series, two representative compounds (6-48 and 6-51) were selected and tested for the evaluation of anticancer effects in vivo using tumor-bearing mice. Compound 6-48 effectively reduced tumor growth (42.3% reduction in size) at the dose of 100 mg/kg. We believe that compound 6-48 will serve as a good lead compound for antimitotic and vascular-disrupting agents; further investigation to improve the in vivo efficacy of this series is underway.

  DOI：

  10.1021/jm400840p

文献信息

• Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1645556A1

  公开（公告）日：2006-04-12

  The invention relates to arylpiperazine-benzoylamide derivatives of formula (I) wherein A, X1, X2, n and R1 to R10 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.

  该发明涉及式(I)的芳基哌嗪-苯甲酰胺衍生物，其中A、X1、X2、n和R1至R10的定义如权利要求1所述，适用于治疗由细胞过度或异常增殖特征的疾病，并用于制备药物组合物。
• Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy
  作者：Min Jeong Choi、Eun Sun No、Dhanaji Achyutrao Thorat、Jae Wan Jang、Hakkyun Yang、Jaeick Lee、Hyunah Choo、Soo Jin Kim、Chang Sik Lee、Soo Young Ko、Jiyoun Lee、GhilSoo Nam、Ae Nim Pae

  DOI：10.1021/jm400840p

  日期：2013.11.27

  A series of aryloxazole, thiazole, and isoxazole derivatives was synthesized as vascular-targeting anticancer agents. Antiproliferative activity and tumor vascular-disrupting activity of all of the synthesized compounds were tested in vitro using various human cancer cell lines and HUVECs (human umbilical vein endothelial cells). Several compounds with an arylpiperazinyl oxazole core showed excellent cytotoxicity and metabolic stability in vitro. Among this series, two representative compounds (6-48 and 6-51) were selected and tested for the evaluation of anticancer effects in vivo using tumor-bearing mice. Compound 6-48 effectively reduced tumor growth (42.3% reduction in size) at the dose of 100 mg/kg. We believe that compound 6-48 will serve as a good lead compound for antimitotic and vascular-disrupting agents; further investigation to improve the in vivo efficacy of this series is underway.